Biomarkers for Post-treatment Control in HIV: International Study of the EU2Cure Research Consortium (Phase I)
18h agoen
From the article
Conditions : HIV Interventions : Other: No Intervention: Observational Cohort Sponsors : Erasmus Medical Center; EU2Cure consortium; Radboud University Medical Center; European Aids Treatment Group (EATG), Brussels, Belgium; University Hospital, Ghent; University Ghent; Oslo University Hospital; Charite University, Berlin, Germany; Institut Pasteur; University of Aarhus; IrsiCaixa; Fundació Lluita contra les Infeccions; IRCCS San Raffaele; Imperial College London; University of Oxford; Guy's and St Thomas' NHS Foundation Trust; Chelsea and Westminster Hospital, UK; Pomeranian Medical University Szczecin; Hospital Universitari Vall d'Hebron Research Institute; Medical University of Warsaw; Centre Hospitalier Universitaire Vaudois Not yet recruiting
Continue reading on clinicaltrials.govYou might also wanna read
Phase 1 trial finds triple monoclonal antibody combination safe and effective for HIV-1 prevention
This phase 1, multicentre, randomised, open-label trial (HVTN 140/HPTN 101 part B) evaluated the safety, pharmacokinetics, and neutralisatio
thelancet.com·7d ago
Stewardship / Resistance Scan for Apr 02, 2020
cahfs.umn.edu·6y ago
Efficient mRNA delivery to resting T cells to reverse HIV latency
nature.com·1y ago
<![CDATA[Functional Cure of Hepatitis B Infections Among Patients Coinfected With HIV]]>
Pharmacy Times·3d ago
Modelling Study Projects Rapid Growth in Radioligand Therapy Patient Populations Across EU and UK Healthcare Systems
This modelling study estimates the future patient populations eligible for radioligand therapies (RLTs) across EU-27 member states and the U
thelancet.com·1mo ago
Genome-wide CRISPR screens identify host factors that promote and restrict HIV infection in primary CD4+ T cells
This article describes a systematic genome-wide CRISPR activation (CRISPRa) and CRISPR knockout screening approach in primary human CD4+ T c
cell.com·28d ago
Comments
Sign in to join the conversation.
No comments yet. Be the first.